TY - JOUR T1 - Machine learning-based prediction of response to PARP inhibition across cancer types JF - medRxiv DO - 10.1101/19007757 SP - 19007757 AU - Katherine E. Hill AU - Ahmed Rattani AU - Christopher E. Lietz AU - Cassandra Garbutt AU - Edwin Choy AU - Gregory M. Cote AU - Aedin Culhane AU - Andrew D. Kelly AU - Benjamin Haibe-Kains AU - Dimitrios Spentzos Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/09/27/19007757.abstract N2 - PARP inhibitors (PARPi) are FDA approved for the treatment of BRCA1/2 deficient breast and ovarian cancer, but a growing body of pre-clinical evidence suggests the drug class holds therapeutic potential in other cancer types, independent of BRCA1/2 status. Large-scale pharmacogenomic datasets offer the opportunity to develop predictors of response to PARPiā€™s in many cancer types, expanding their potential clinical applicability. Response to the PARPi olaparib was used to identify a multi-gene PARPi response signature in a large in vitro dataset including multiple cancer types, such as breast, ovarian, pancreatic, lung cancer, osteosarcoma and Ewing sarcoma, using machine learning approaches. The signature was validated on multiple independent in vitro datasets, also testing for response to another PARPi, rucaparib, as well as two clinical datasets using the cisplatin response as a surrogate for PARPi response. Finally, integrative pharmacogenomic analysis was performed to identify drugs which may be effective in PARPi resistant tumors. A PARPi response signature was defined as the 50 most differentially transcribed genes between PARPi resistant and sensitive cell lines from several different cancer types. Cross validated predictors generated with LASSO logistic regression using the PARPi signature genes accurately predicted PARPi response in a training set of olaparib treated cell lines (80-89%), an independent olaparib treated in vitro dataset (66-77%), and an independent rucaparib treated in vitro dataset (80-87%). The PARPi signature also significantly predicted in vitro breast cancer response to olaparib in another separate experimental dataset. The signature also predicted clinical response to cisplatin and survival in human ovarian cancer and osteosarcoma datasets. Robust transcriptional differences between PARPi sensitive and resistant tumors accurately predict PARPi response in vitro and cisplatin response in vivo for multiple tumor types with or without known BRCA1/2 deficiency. These signatures may prove useful for predicting response in patients treated with PARP inhibitors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementB.H.-K. was supported by the Gattuso Slaight Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre, the Canadian Institute of Health Research, Natural Sciences and Engineering Research Council, and the Terry Fox Research Institute and the Stand Up To Cancer Canada. The research was supported by a Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team Research Funding, with supplemental support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario (Funding Award Number: SU2C-AACR-DT-18-15). Stand Up To Cancer Canada is a program of the Entertainment Industry Foundation Canada. Research funding is administered by the American Association for Cancer Research International-Canada, the Scientific Partner of SU2C Canada. D.S. was supported by National Institute of Health grant RO1CA178908, and the Casper Colson philanthropic donation to D.S and the Sarcoma Program at the MGH Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe data analyzed in this study are publicly available at the Genomics of Drug Sensitivity in Cancer resource page (https://www.cancerrxgene.org/downloads/bulk_download), the TCGA GDC data portal (https://portal.gdc.cancer.gov/projects/TCGA-OV), ArrayExpress (E-TABM-157), and Gene Expression Omnibus (GSE:39058). https://www.cancerrxgene.org/downloads/bulk_download https://portal.gdc.cancer.gov/projects/TCGA-OV https://www.ncbi.nlm.nih.gov/bioproject/PRJNA169852 ER -